Skip to main content
SpringerLink
Log in

Assessment of Hematological Malignancies with PET

  • Chapter
Clinical PET

Part of the book series: Developments in Nuclear Medicine ((DNUM,volume 28))

Abstract

Hematological malignancies mainly comprise the various types of malignant lymphoma and multiple myeloma. While diagnosis of the latter is based on laboratory findings and bone marrow biopsy, the most important clinical sign of malignant lymphoma is lymphnode enlargement. Imaging procedures play therefore an important role for staging as well as treatment control. Plain x-ray techniques, computed tomography, and ultrasonography are all aiming at evaluation of lymphnode size assuming that lymphnode involvement is present if the diameter is exceeding 1.0–1.5cm [1,2]. However, even smaller lymphnodes may contain lymphoma infiltrations. On the other hand, lymphnode enlargement may also be due to inflammatory or granulomatous disease. Therefore sensitivity as well as specificity of morphologically based lymphnode evaluation is limited. The same is true for the assessment of liver or spleen and treatment control. While reduction of lymphoma size is generally accepted as sign of response, lymphoma persistence is difficult to interprete. Residual masses may contain viable lymphoma, necrotic tissue, or variable amounts of both. Until now definite differentiation can only be achieved by biopsy which inheres the possibility of sampling errors and serious side effects. Alternative non-invasive diagnostic approaches are therefore needed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Genereux GP, Howie JL. Normal mediastinal lymphnode size and number: CT and anatomic study. AJR 1984; 142: 1095–1100.

    PubMed  CAS  Google Scholar 

  2. Müller NL, Webb WR, Gamsu G. Paratracheal lymphadenopathy: radiographic findings and correlation with CT. Radiology 1985; 165: 761–765.

    Google Scholar 

  3. McLaughlin A, Magee MA, Greenough R, et al.. Current role of gallium scanning in the management of lymphoma. Eur J Nucl Med 1990; 16: 755–771.

    Article  PubMed  CAS  Google Scholar 

  4. Iosilevsky G, Front D, Bettman L, Hardoff R, Ben-Arieh Y. Uptake of gallium-67 citrate and 2-H-3 deoxyglucose in the tumor model following chemotherapy and radiotherapy. J Nucl Med 1985; 26: 278–282.

    PubMed  CAS  Google Scholar 

  5. Tumeh S, Rosenthal DS, Kaplan WD, English RJ, Holman BL. Lymphoma: evaluation with Ga-67 SPECT. Radiology 1987; 164: 111–114.

    PubMed  CAS  Google Scholar 

  6. Front D, Bar-Shalom R, Epelbaum R, et al.. Early detection of lymphoma recurrence by gallium-67 scintigraphy. J Nucl Med 1993; 34: 2101–2104.

    PubMed  CAS  Google Scholar 

  7. Kostakogu L, Yeh SDJ, Portlock C, et al.. Validation of gallium-67-citrate single-photon emission computed tomography in biopsy-confirmed residual Hodgkin’s disease in the mediastinum. J Nucl Med 1992; 33: 345–350.

    Google Scholar 

  8. Johannsson L, Mattsson S, Nosslin B, Leide-Svegborn S. Effective dose from radiopharmaceuticals. Eur J Nucl Med 1992; 19: 933–938.

    Article  Google Scholar 

  9. Bares R, Galonska P, Dempke W, Handt St., Büll U, Osieka R. Somatostatin receptor scintigraphy in malignant lymphoma: first results and comparison with glucose metabolism measured by positron emission tomography. Horm Metab Res 1993; 27 (suppl): 56–58.

    CAS  Google Scholar 

  10. Lipp RW, Silly H, Ranner G, et al.. Radiolabeled octreotide for the demonstration of somatostatin receptors in malignant lymphoma and lymphadenopathy. J Nucl Med 1995; 36: 13–18.

    PubMed  CAS  Google Scholar 

  11. Reubi JC, Waser B, van Hagen M, et al.. In vitro and in vivo detection of somatostatin receptors in human malignant lymphomas. Int J Cancer 1992; 50: 895–900.

    Article  PubMed  CAS  Google Scholar 

  12. Sehweil AM, McKillop JH, Milroy R, et al.. 201T1 scintigraphy in the staging of lung cancer, breast cancer, and lymphoma. Nucl Med Commun 1990; 11: 263–269.

    Article  PubMed  CAS  Google Scholar 

  13. Piwnica-Worms D, Chiu ML, Budding M, Kronauge JF, Kramer RA, Croop JM. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res 1993; 53: 977–984.

    PubMed  CAS  Google Scholar 

  14. Dimitrakopoulou-Strauss A, Strauss LG, Goldschmidt H, Lorenz WJ, van Kaick G. PET with FDG and SPECT with Tc-99m-sestamibi for therapy management in patients with treated malignant lymphomas. J Nucl Med 1994; 35: 231 P.

    Google Scholar 

  15. Paul R. Comparison of fluorine-18–2-Fluorodeoxyglucose and gallium-67 citrate imaging for detection of lymphoma. J Nucl Med 1987; 28: 288–292.

    PubMed  CAS  Google Scholar 

  16. Okada J, Yoshikawa K, Imazeki K, et al.. The use of FDG-PET in the detection and management of malignant lymphoma: correlation of uptake with prognosis. J Nucl Med 1991; 32: 686–691.

    PubMed  CAS  Google Scholar 

  17. Okada J, Yoshikawa K, Itami M, et al.. Positron emission tomography using fluorine18-fluorodeoxyglucose in malignant lymphoma: a comparison with proliferative activity. J Nucl Med 1992; 33: 325–329.

    PubMed  CAS  Google Scholar 

  18. Leskinen-Kallio S, Ruotsalainen U, Nagren K, Teräs M, Joensuu H. Uptake of carbon- 11-methionine and fluorodeoxyglucose in non-Hodgkin’s lymphoma: a PET study. J Nucl Med 1991; 32: 1211–1218.

    PubMed  CAS  Google Scholar 

  19. Schönberger JA, Stollfuß JC, Kocher F, et al.. Whole body 18-FDG-PET for staging of malignant lymphomas. Eur J Nucl Med 1994; 21: 727.

    Google Scholar 

  20. Hoh CK, Glaspy JA, Hawkins RA, et al.. Utility of whole body PET in the staging of Hodgkin’s disease and lymphoma. J Nucl Med 1994; 35: 221 P.

    Google Scholar 

  21. Newman JS, Francis IR, Kaminski MS, Wahl RL. Imaging of lymphomawith PET with 2-(F-18)-Fluoro-2-deoxy-D-glucose: Correlation with CT. Radiology 1994; 190: 111–116.

    PubMed  CAS  Google Scholar 

  22. Bares R, Altehoefer C, Cremerius U, et al.. FDG-PET for metabolic classification of residual lymphoma masses after chemotherapy. J Nucl Med 1994; 35: 131 P.

    Google Scholar 

  23. Garcia JR, Kim EE, Wong FCL, et al.. Ga-67 citrate scan in the differentiation of bone lymphoma from post-treatment changes: comparison with FDG-PET scan. J Nucl Med 1994; 35: 131 P.

    Google Scholar 

  24. Hoekstra OS, Ossenkoppele GJ, Golding R, et al.. Early treatment response in malignant lymphoma, as determined by planar Fluorine-18-Fluorodeoxyglucose scintigraphy. J Nucl Med 1993; 34: 1706–1710.

    PubMed  CAS  Google Scholar 

  25. Martiat Ph, Ferrant A, Labar D, et al.. In vivo measurement of carbon-11 thymidine uptake in non-Hodgkin’s lymphoma using positron emission tomography. J Nucl Med 1988; 29: 1633–1637.

    PubMed  CAS  Google Scholar 

  26. Kubota K, Ishiwata K, Kubota R, et al.. Tracer feasibility for monitoring tumor radiotherapy: a quadruple tracer study with fluorine-18-fluorodeoxyglucose, or fluorine-18-fluorodeoxyuridine, L[methyl-14C]methionine, [6–3H]thymidine, and gallium-67. J Nucl Med 1991; 32: 2118–2123.

    PubMed  CAS  Google Scholar 

  27. Hoffman JM, Waskin HA, Schifter T, et al.. FDG-PET in differentiating lymphoma from nonmalignant central nervous system lesions in patients with AIDS. J Nucl Med 1993; 34: 567–575.

    PubMed  CAS  Google Scholar 

  28. Woodard HQ, Gigler RE, Freed B, Russ G. Expression of tissue isotope distribution. J Nucl Med 1975; 16: 958–959.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Roland Bares
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Nuclear Medicine, Eberhard-Karls-University, Roentgenweg 13, D-72076, Tuebingen, Germany

    Roland B. Bares

  2. INB-CNR, Department of Nuclear Medicine, University of Milan, Scientific Institute H.S., Via Olgettina 60, Raffaele, Milan, I- 20132, Italy

    Giovanni Lucignani

Rights and permissions

Reprints and permissions

Copyright information

© 1996 Kluwer Academic Publishers

About this chapter

Cite this chapter

Bares, R. (1996). Assessment of Hematological Malignancies with PET. In: Bares, R.B., Lucignani, G. (eds) Clinical PET. Developments in Nuclear Medicine, vol 28. Springer, Dordrecht. https://doi.org/10.1007/978-94-009-0309-8_7

Download citation

  • DOI: https://doi.org/10.1007/978-94-009-0309-8_7

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-010-6624-2

  • Online ISBN: 978-94-009-0309-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation